Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.64 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720238 | 0.82 | FFAR1 (0.56) | GRM4FFAR1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL10020221 | 0.82 | FFAR1 (0.56) | GRM4FFAR1GRM5NPC1RAB9A | |
| SCHEMBL708798 | 0.82 | FFAR1 (0.56) | GRM4FFAR1GRM5KCNH2 | |
| SCHEMBL28026976 | 0.80 | GRM4 (0.50) | GRM4FFAR1GRM5 | |
| SCHEMBL10338425 | 0.78 | GRM4 (1.00) | GRM4GRM5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13138542 | 0.75 | FFAR1 (0.44) | GRM4FFAR1GRM5 | |
| SCHEMBL20576439 | 0.74 | GRM5 (0.44) | GRM4FFAR1GRM5NPC1RAB9A | |
| SCHEMBL13388985 | 0.74 | FFAR1 (0.57) | FFAR1GRM5KDM4EALDH1A1 | |
| SCHEMBL102806 | 0.74 | GRM5 (0.56) | GRM4FFAR1GRM5RAB9ASMN1; SMN2 | |
| SCHEMBL29089197 | 0.73 | GRM5 (0.61) | GRM4GRM5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2072165-A | — | — | None | — | — | JP | disclosed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3893879-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| CN-113164477-A | Pyrazolopyridine inhibitors of C-JUN-N-terminal kinase and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123925-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
| JP-H0272165-A | 4-STYRYLPYRIMIDINE DERIVATIVE AND PLANT GROWTH PROMOTER CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | KUMAZAWA ZENZABURO | 1990-03-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073512-A1 | PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF | MAP3K3, MAP2K3, MAP3K2 | GRM4 4646/4885FFAR1 3406/4885GRM5 4009/4885 |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | GRM4 1603/4885FFAR1 4476/4885GRM5 1840/4885 |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | GRM4 1603/4885FFAR1 4476/4885GRM5 1840/4885 |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | GRM4 1603/4885FFAR1 4476/4885GRM5 1840/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | GRM4 4038/4885FFAR1 1953/4885GRM5 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.